Malabsorption Clinical Trials

• Body mass index (BMI) of 18 to 40 (kg/m2) at screening.

• Willingness to ingest a gluten-free product and Simulated Inadvertent Gluten Exposure (SIGE) products as per the study protocol.

• History of medically diagnosed, and adequately documented (i.e., included in the participant's medical records), CeD

• Attempting a GFD for at least 12 months prior to the screening visit.

• \- The participants should be instructed not to alter dietary habits including a GFD during the study period.

• Valid results from central testing of blood documenting a positive result for the HLA DQ2.5 genotype (HLA-DQA1\*05 and HLA-DQB1\*02) (homozygous or heterozygous).

• Experienced at least 2 gluten-related symptom events (i.e., 2 different gluten-related symptoms which are diarrhea, abdominal pain, bloating, nausea, tiredness or 1 gluten-related symptom occurred twice) within a month before the screening.

• Willingness to undergo 2 on-study upper gastrointestinal endoscopies with duodenal biopsies.

• Presence of ongoing duodenal mucosal damage defined as Vh:Cd of 2.5 or less